Lenalidomide Accord 2.5 mg hard caps. 21 (21 x 1) UD
Active ingredient: Lenalidomide
View notice details →News topic
Start: 2024-06
All current shortage notices related to Start: 2024-06, structured by product, country, active ingredient and reporting period.
6 noticesZypadhera 405 mg inj. susp. prol.-rel. (pwdr. + solv.) i.m. vial 405 mg + 3 ml
Active ingredient: Olanzapine
View notice details →Zypadhera 300 mg inj. susp. prol.-rel. (pwdr. + solv.) i.m. vial 300 mg + 3 ml
Active ingredient: Olanzapine
View notice details →Zypadhera 210 mg inj. susp. prol.-rel. (pwdr. + solv.) i.m. vial 210 mg + 3 ml
Active ingredient: Olanzapine
View notice details →Quetiapin Retard Sandoz 50 mg tabl. prol.-rel. 30
Active ingredient: Quetiapine
View notice details →Lenalidomide Accord 2.5 mg harde caps. 21 (21 x 1) UD
Active ingredient: Lenalidomide
View notice details →Plan supply. Connect sourcing and warehousing.
For pharmacies, wholesalers and manufacturers: choose the service matching your operational need.
Improve sourcing and supply availability
Researching this shortage professionally? We assess sourcing routes, suppliers and cross-border supply against your requirements. A notice does not confirm stock availability.
Send a sourcing enquiry →Pharma warehouse and pharmaceutical warehousing in Cheb
Medicine storage, batch and expiry control, picking and distribution for Germany and Europe. We agree the storage profile, temperature and capacity with you.
Request warehouse capacity →